Science, Entrepreneurship & Building the MERLN Research Institute – Prof. Clemens van Blitterswijk

What does it take to build one of Europe’s leading research institutes in Regenerative Medicine? In this inspiring conversation, we speak with Professor Clemens van Blitterswijk, a pioneer in tissue engineering and founder of the MERLN Institute for Technology-Inspired Regenerative Medicine in Maastricht, the Netherlands.The conversation touches on many turning points: building companies during crises, navigating the choice between academia and business, and leading a remarkable transfer of sixteen colleagues to establish a new research institute.Clemens reflects on the right time to commercialize discoveries and how coincidental findings can lead to breakthroughs in top journals. He shares insights on helping startups through RegMed XB and the delicate art of knowing when to push forward and when to stop. We also discussed why art and science are more closely related than we think.From biomaterials that grow bone to Clemens’ vision for high-throughput technologies, this interview reveals a scientist-entrepreneur who has not only advanced regenerative medicine but also built bridges between universities, startups, and patients – pushing regenerative medicine field forward. Timestamps:00:00 Introduction to Biomed unleashed00:27 Guest Introduction01:27 Welcome02:00 What sparked Prof. Clemens van Blitterswijk’s interest in regenerative medicine?03:40 How to get a job?05:13 Differences in setting up your own lab back then and now06:10 Founding companies09:33 Combining research and entrepreneurship as a profession 11:05 Clemens’ thoughts about combining academia and entrepreneurship when he was a bachelor student12:22 Interest in science when Clemens was a child13:10 Illusion of having everything under control14:10 Building company during crisis16:00 Advice to people to keep going in difficult life situation18:11 Dilemma: academia research or business management?21:05 Leaving one university and transferring your lab to another, why and how?22:45 Why coming to Maastricht (the Netherlands)?24:27 What to do when you do not agree with the situation?25:08 Mega transfer of 16 staff members from one university to another and building the MERLN Institute for Technology Inspired Regenerative Medicine in Maastricht (the Netherlands)27:12 Balance of freedom and structure in the MERLN Institute 30:00 Believe or be critical? How to keep the same sense of purpose in large organizations? 32:18 Bringing science to application to help patients33:57 Materials that can grow bone tissue (without cells) even in skin - Kuros Biosciences37:18 Helping new regenerative medicine companies (startups) - RegMed XB40:16 Complexity of financing research42:25 Fostering collaborations between universities in the Netherlands - RegMed XB44:36 Thoughts on future collaborations between universities in Europe45:36 Retirement and influence 48:48 Helping university spin-offs 49:45 What is the right time to start commercializing your research?51:59 Coincidental findings in research that lead to publications in Nature and Advanced Materials54:36 Serendipity and talent to see when something is special56:03 Is it possible to develop the talent of seeing when something is special?58:11 Being able to stop at a right moment is essential58:34 Art and science1:00:05 The project that Prof. Clemens van Blitterswijk is most proud of1:02:30 High throughput technologies for research1:05:22 Abandon fundamental scientific approach of first understanding and then applying1:05:35 Lab and cell organization are more similar than we think1:07:08 How to have a satisfying scientific career?1:08:22 Last question!1:09:09 Meet Biomed Unleashed Team1:09:39 Biomed Unleashed OutroHost: Alisa OvsiannikovaWriters: Alisa Ovsiannikova, Misha BagirovEditor: Misha BagirovPromotion: Amaliya Bagdasaryan, Alba Villagrasa MartinCoordinator: Alisa OvsiannikovaMERLN Institute for Technology-Inspired Regenerative Medicine https://merlninstitute.com

There are no comments yet.

Please log in to write the first comment.